[1] Gutiérrez E, Flammer AJ, Lerman LO, et al. Endothelial
dysfunction over the course of coronary artery disease [J] .
Eur Heart, 2013,34(41):3175-3181.
[2] Burger D, Schock S, Thompson CS, et al. Microparticles:
biomarkers and beyond [J]. Clin Sci (Lond), 2013,124
(7):423-441.
[3] Montoro-García S, Shantsila E, Wrigley BJ, et al. Smallsize
Microparticles as Indicators of Acute Decompensated
State in Ischemic Heart Failure [J]. Rev Esp Cardiol (Engl
Ed), 2015,68(11):951-958.
[4] Di Y, Zhang D, Hu T, et al. miR-23 regulate the pathogenesis
of patients with coronary artery disease [J]. Int J
Clin Exp Med, 2015,8(7):11759-11769.
[5] Jansen F, Yang X, Baumann K, et al. Endothelial microparticles
reduce ICAM- 1 expression in microRNA- 222-
dependent mechanism [J]. J Cell Mol Med, 2015,19(9):
2202-2214.
[6] Fan Y, Wang L, Li Y, et al. Quantification of endothelial
microparticles on modified cytometric bead as say andprognosis
in chest pain patients [J]. Circ J, 2014,78(1):206-
214.
[7] 李红昆,陆永光.内皮细胞微粒与冠心病关系的研究进展[J].广西
医学杂志,2013,35(1):104-106.
[8] Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis
[J]. Curr Opin Lipidol, 2003,14(5):469-475.
[9] Biasucci LM, Porto I, Di Vito L, et al. Differences in
microparticle release in patients with acute coronary syndrome
and stable angina [J]. Circ J, 2012,76(9):2174-2182.
[10] Castelli WP, Garrison RJ, Wilson PW, et al. Incidence
of coronary heart disease and lipoprotein cholesterol levels.
The Framingham Study [J]. JAMA, 1986,256(20):2835-
2838.
[11] Nagao M, Nakajima H, Toh R, et al. Cardioprotective
Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic
Action [J]. J Atheroscler Thromb, 2018. [Epub
ahead of print]
[12] Zhang HW, Zhao X, Guo YL, et al. Elevated lipoprotein
(a) levels are associated with the presence and severity of
coronary artery disease in patients with type2 diabetes mellitus
[J]. Nutr Metab Cardiovasc Dis, 2018,28(10):980-986.